Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. Issue 2 (August 2017)

• Record Type: Journal Article
• Authors: Nigam, Kumari; Sharma, Divya; Gupta, Anil Kumar; Rawat, Vivek Singh; Rufai, Syed Beenish; Singh, Amit; Singh, Jitendra; Kumar, Parveen; Sankar, Manimuthu Mani; Singh, Sarman
• Is Part Of: Journal of infection. Volume 75:Issue 2(2017)
• Page Start: 125
• Page End: 131
• Publication Date: 2017-08
• Subjects: Xpert MTB/RIF -- Tuberculosis -- Meningitis -- MGIT-960 -- Cerebrospinal fluid; Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2017.04.010
• Languages: English
• ISSNs: 0163-4453

Abstract

Summary: Objective: Tuberculous meningitis (TBM) is the most severe form of extra-pulmonary tuberculosis (TB) due to association of diseases with high rates of mortality and morbidity. Diagnosis continues to be a clinical challenge as microbiological confirmation is rare and time consuming resulting in delayed treatment. Xpert MTB/RIF assay is a rapid and simple test, which has been endorsed by World Health Organization as an initial diagnostic test for the diagnosis of TBM. However, evidence still lacks for its performance on cerebrospinal fluid (CSF) for the diagnosis of TBM especially from India. Methods: A total of 267 CSF samples from patients with high clinico-radiological suspicion of TBM were included in this study. Ziehl–Neelsen (ZN) staining, BACTEC Mycobacterial Growth Indicator Tube (MGIT-960) culture system, and Xpert MTB/RIF assay (using cartridge version G4) were tested on all samples. Results: Of total 267 samples, all were negative for smear AFB and 52 (19.5%) were culture positive by MGIT-960 culture system. However, out of 52 (19.5%) cultures detected positive by MGIT-960, 5 (9.6%) were detected as resistant to rifampicin. Xpert MTB/RIF assay was positive in 38 (14.2%) samples and negative in 223 (83.5%) samples. Cartridge error was detected in 6 (2.2%) samples, which could not be repeated due to insufficient sample volume. The sensitivity and specificity of Xpert MTB/RIF assay in comparison to MGIT-960 was 55.1% (95%, CI: 40.2–69.3) and 94.8% (95%, CI: 90.9–97.4) respectively. Overall, Xpert MTB/RIF assay detected 38 (14.2%) as positive for MTB of which 4 (10.5%), 31 (81.6%) and 3 (7.9%) were found to be rifampicin resistant, sensitive and indeterminate respectively. Conclusion: Xpert MTB/RIF assay showed lower sensitivity as compared to MGIT 960 culture for the diagnosis of TBM from CSF samples. Highlights: Tuberculous meningitis (TBM) has high mortality and morbidity, if not managed early. Utility of Xpert/MTB Rif assay was evaluated on 267 CSF samples from TBM patients. In comparison to culture, it showed 55.1% sensitivity but 94.8% specificity. Overall, it could detect MTB only in 38 (14.2%) samples. Of the 38 positive samples, 10.5% were found to have MDR (rifampicin resistant) TB.